Catalyst Wire Dossier Catalyst Wire Dossier

Ivemend

fosaprepitant · Merck Sharp & Dohme B.V.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ivemend, covering 2025-11-05 to 2025-11-05. Get the full timeline:

Most recent: EMA Authorised: Ivemend (fosaprepitant) — Merck Sharp & Dohme B.V.

See pricing